Alarming Study Reveals Safety Limits are Exceeded for Mercury Exposure from Dental Amalgams in Pregnant Women in the U.S.
14 févr. 2024 11h00 HE
|
International Academy of Oral Medicine & Toxicology
A New Study Reveals that Mercury Exposure from Dental Amalgam Fillings in Pregnant Women Exceed Safety Limits
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
12 févr. 2024 07h00 HE
|
Optimi Health Corp.
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
09 févr. 2024 07h00 HE
|
OKYO Pharma LTD
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe...
Optimi Announces Non-Brokered Private Placement
08 févr. 2024 07h30 HE
|
Optimi Health Corp.
Optimi Announces Non-Brokered Private Placement
Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners
06 févr. 2024 07h30 HE
|
Optimi Health Corp.
Highlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.Optimi experts will address critical inquiries which still...
Qure.ai adds new FDA breakthrough device status to growing list of regulatory milestones
05 févr. 2024 09h00 HE
|
Qure.ai Technologies Private Limited
NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Medical imaging AI innovator, Qure.ai, has received breakthrough device designation from the Food and Drug Administration's (FDA) Center for Devices and...
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
02 févr. 2024 16h05 HE
|
NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
Triastek's 3D Printed Gastric Retention Product T22 Receives FDA Clearance of IND Application
31 janv. 2024 08h00 HE
|
Triastek, Inc.
NANJING, CHINA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Triastek's 3D printed gastric retention product T22 received IND clearance from the FDA, becoming the world's first 3D printed gastric retention...
FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro
30 janv. 2024 09h18 HE
|
Magstim EGI
FDA clears Magstim TMS System Horizon 3.0 with StimGuide Pro providing treatment for patients patients with depressive or obsessive-compulsive conditions
Theratechnologies reçoit une lettre de non-approbation (CRL) de la FDA concernant son supplément à la licence de produit biologique (sBLA) pour la formulation F8 de la tésamoréline
24 janv. 2024 07h00 HE
|
Theratechnologies
La FDA demande des clarifications sur la chimie, la fabrication et les contrôles ainsi que des informations supplémentaires sur l'immunogénicitéLa CRL n'affecte pas la disponibilité commerciale...